74. 下垂体性PRL分泌亢進症
[臨床試験数:18,薬物数:33(DrugBank:10),標的遺伝子数:16,標的パスウェイ数:63

Searched query = "Prolactin secreting pituitary adenoma", "Pituitary PRL secretion hyperthyroidism", "Prolactinoma", "Prolactin secreting adenoma"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03400865
(ClinicalTrials.gov)
October 25, 20188/1/2018Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant ProlactinomasThe Effect of Combined Treatment of Cabergoline With Hydroxychloroquine/Chloroquine for Resistant ProlactinomasResistance, Disease;ProlactinomaDrug: HCQ/CQ and CAB combined treatmentZhebao WuXinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General HospitalNot yet recruiting18 Years70 YearsAll30N/AChina
2NCT03457389
(ClinicalTrials.gov)
February 22, 201823/1/2018Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With ProlactinomaComparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma: A Prospective, Randomized, Open Label, Active-controlled, Clinical TrialPituitary Adenoma;Prolactinoma;Pituitary Tumor;Recurrence TumorDrug: CabergolineSeoul National University HospitalNULLRecruiting19 YearsN/AAll68N/AKorea, Republic of
3NCT01620138
(ClinicalTrials.gov)
March 201018/9/2011Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant ProlactinomasSomatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine AgonistNon-functioning Pituitary Adenomas;ProlactinomasDrug: Pasireotide;Drug: cabergolineUniversidade Federal do Rio de JaneiroNULLCompleted18 YearsN/AAll21Phase 2;Phase 3Brazil
4NCT00460616
(ClinicalTrials.gov)
January 200713/4/2007Cardiac Valve Complications in Prolactinomas Treated With CabergolineObservational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With CabergolineProlactinomasDrug: CabergolineFederico II UniversityNULLCompleted18 Years65 YearsBoth50Italy